Metabolic syndrome in patients with bipolar disorder

Vuksan-Ćusa, Bjanka; Nadj, S.; Marčinko, Darko; Jakovljević, Miro; Topić, Radmila

doi:10.1016/j.eurpsy.2008.01.449

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sample sizes of these studies have varied from 15 to 822 patients and the rates of MetS vary widely from 16.7% to 67%. Of the 34 studies shown in [ Table 2 ], some authors have published the data of the same group of patients with varying sample size[ 65 – 68 ] and others have published the data separately for various definitions[ 45 46 ] of MetS. More than half of the available studies (18 out of 34) have included less than 100 patients.…”

Section: Prevalence Of Mets In Bpadmentioning

confidence: 99%

“…[ 40 51 ] One study reported that women had peak of prevalence of MetS in the ≥60 years group, while men displayed high rates even in the young age groups. [ 59 ] Some of the studies have reported that MetS is more common in females,[ 62 ] while others have reported no gender differences in the prevalence rates of MetS[ 38 51 56 58 61 63 65 69 ] and an occasional study has reported higher prevalence in males,[ 60 ] especially in younger age group. [ 37 ]…”

Section: Prevalence Of Components Of Metsmentioning

confidence: 99%

“…Maina et al [55] $ 185 Italy NCEP ATP III 27.9 McIntyre et al [56] Canada NCEP ATP III 32.6 Women-13.2% Men-17% Rahman et al [57] Malaysia IDF 42 15% in schizophrenia group Salvi et al [58] Italy 51.7 NCEP ATP III IDF 25.3 30 Salvi et al [59] 200 Italy 50.9 NCEP ATP III 26.5 Sanchez et al [60] 532 [61] 178 Spain 49.9 NCEP ATP III 24.7 14.4% 26.2% for schizophrenia Teixeira and Rocha [62] Brazil [65] Croatia 41.1 NCEP ATP III 35.3 Vuksan-Cusa et al [66] Croatia 41.1 27.5 Vuksan-Cusa et al [67] Croatia 31 37% in schizophrenia Vuksan-Cusa et al [68] Croatia 31 37% in schizophrenia Yumru et al [69] 125 [47,49,64] Except for one study, all of these are cross-sectional investigations and do not provide data on how the rates of MetS change over time. Kemp et al [52] When one takes a closer look at these studies it is evident that at least 27 are from the Western countries, 2 from 2 from Brazil, 2 from Korea/Taiwan, 1 each from Turkey, Malaysia and India.…”

Section: 6% In Schizophrenia Groupmentioning

confidence: 99%

“…Chang et al [39] 61 18.6 13.7 53 36.8 Corell et al [40] 33.8 54.0 32.4 67.6 46.6 Dmello et al [41] 41 62 48 71 Elmslie et al [3] 85 50 6 63 40 Fagiolini et al [43] 49 39 8 23 41 Garcia-Portilla et al [45] 53.8 20.9 12.2 38.2 36.1 Khatana et al [53] 46.5 78.1 20.6 48.4 49.3 Kim et al [70] 30.4 30.4 43.5 Lee et al [54] 40.8 47.4 25.7 15 32.9 32.9 Maina et al [55] 48.9 53 11.5 33.3 36.6 McIntyre et al [56] 41.1 27.6 6.1 36.4 38.8 Salvi et al [57] 50 40 11 32.3 34.7 Sicras et al [61] 33.1 29.8 16.9 54.5 23.0 Sicras-Maniar et al [71] 38.3 32.8 18.0 52.3 22.7 Van Winkel et al [63] [64] 33.9 50.9 25.0 32.1 Vuksan Cusa et al [65] 47 50 23.5 23.5 58.8 Vuksan Cusa et al [68] 36.1 41.7 25.7 25.5 47.2 prevalence of waist circumference and blood pressure indicates that monitoring them may be more useful and cost effective.…”

Section: Low High Density Lipoprotein High Triglyceridementioning

confidence: 99%

See 3 more Smart Citations

Metabolic Syndrome in Bipolar Disorders

Grover

Malhotra

Chakrabarti

et al. 2012

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

To review the data with respect to prevalence and risk factors of metabolic syndrome (MetS) in bipolar disorder patients. Electronic searches were done in PUBMED, Google Scholar and Science direct. From 2004 to June 2011, 34 articles were found which reported on the prevalence of MetS. The sample size of these studies varied from 15 to 822 patients, and the rates of MetS vary widely from 16.7% to 67% across different studies. None of the sociodemographic variable has emerged as a consistent risk factor for MetS. Among the clinical variables longer duration of illness, bipolar disorder- I, with greater number of lifetime depressive and manic episodes, and with more severe and difficult-to-treat index affective episode, with depression at onset and during acute episodes, lower in severity of mania during the index episode, later age of onset at first manic episode, later age at first treatment for the first treatment for both phases, less healthy diet as rated by patients themselves, absence of physical activity and family history of diabetes mellitus have been reported as clinical risk factors of MetS. Data suggests that metabolic syndrome is fairly prevalent in bipolar disorder patients.

show abstract

Section: Prevalence Of Mets In Bpadmentioning

confidence: 99%

Section: Prevalence Of Components Of Metsmentioning

confidence: 99%

Section: 6% In Schizophrenia Groupmentioning

confidence: 99%

Section: Low High Density Lipoprotein High Triglyceridementioning

confidence: 99%

See 2 more Smart Citations

Metabolic Syndrome in Bipolar Disorders

Grover

Malhotra

Chakrabarti

et al. 2012

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

show abstract

“…Dehydroepiandrosterone decreases CORT levels by attenuating the activity of the HPA axis. The ratio of DHEA (or DHEAS, its sulphate ester)/cortisol was shown to be associated with states of anxiety and stress (36,37). We previously demonstrated that DHEA treatment attenuates cocaine acquisition, extinction and reinstatement (27)(28)(29).…”

Section: Discussionmentioning

confidence: 99%

Dehydroepiandrosterone Attenuates Cocaine‐Seeking Behaviour Independently of Corticosterone Fluctuations

Maayan

Hirsh

Yadid

et al. 2015

J Neuroendocrinology

View full text Add to dashboard Cite

The neurosteroid dehydroepiandrosterone (DHEA) is involved in the pathophysiology of several psychiatric disorders, including cocaine addiction. We have previously shown that DHEA attenuates cocaine-seeking behaviour, and also that DHEA decreases corticosterone (CORT) levels in plasma and the prefrontal cortex. Previous studies have found that rats demonstrate cocaine-seeking behaviour only when the level of CORT reaches a minimum threshold. In the present study, we investigated whether the attenuating effect of DHEA on cocaine seeking is a result of it reducing CORT levels rather than a result of any unique neurosteroid properties. Rats received either daily DHEA injections (2 mg/kg, i.p.) alone, daily DHEA (2 mg/kg, i.p.) with CORT infusion (to maintain stable basal levels of CORT; 15 mg/kg, s.c.) or vehicle (i.p.) as control, throughout self-administration training and extinction sessions. We found that both DHEA-treated and DHEA + CORT-treated groups showed a significantly lower number of active lever presses compared to controls throughout training and extinction sessions, as well as at cocaine-primed reinstatement. DHEA-treated rats showed lower CORT levels throughout the experimental phases compared to DHEA + CORT-treated and control rats. Additionally, we show that DHEA administered to cocaine-trained rats throughout extinction sessions, or immediately before reinstatement, attenuated cocaine seeking. These findings indicate that DHEA attenuates cocaine-seeking behaviour independently of fluctuations in CORT levels.

show abstract

Metabolic syndrome in patients with bipolar disorder

Cited by 2 publications

References 0 publications

Metabolic Syndrome in Bipolar Disorders

Metabolic Syndrome in Bipolar Disorders

Dehydroepiandrosterone Attenuates Cocaine‐Seeking Behaviour Independently of Corticosterone Fluctuations

Contact Info

Product

Resources

About